Treatment of salpingitis with pivampicillin. A comparison of twice-daily and thrice-daily dosages.

The efficacy of pivampicillin, administered in a dose of 350 mg three times daily or 500 mg twice daily, was compared in 107 patients with acute salpingitis. Both regimens were equally effective. Fortyseven out of 56 patients given the 500 mg doses were cured and four improved. Of the patients who received the 350 mg doses, 46 out of 51 were cured and three improved. Patients were divided into two groups with severe and mild infections respectively. The 500 mg dose of pivampicillin was significantly more effective in reducing pyrexia in all patients including those with severe infections. Mean treatment duration was shorter in patients with severe infections given 500 mg of pivampicillin twice daily (11.4 days) than in those receiving 350 mg three times daily (14.5 days). Slight gastrointestinal discomfort occurred in 9% of patients receiving the 500 mg dose and in 4% of those receiving the 350 mg dose. The overall incidence of exanthema was about 5%. The twice daily regimen of 500 mg pivampicillin is recommended since it is more practical for the departments concerned and patient compliance is better.
AuthorsG Kvile, P Langeland, B Norling
JournalInfection (Infection) Vol. 8 Issue 1 Pg. 32-6 ( 1980) ISSN: 0300-8126 [Print] GERMANY, WEST
PMID7372355 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Pivampicillin
  • Ampicillin
  • Ampicillin (analogs & derivatives)
  • Female
  • Fever (drug therapy)
  • Humans
  • Pivampicillin (administration & dosage, adverse effects, therapeutic use)
  • Salpingitis (diagnosis, drug therapy)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: